We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 31 for:    cord blood and type 1 diabetes
Previous Study | Return to List | Next Study

Umbilical Cord Blood Infusion to Treat Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00305344
Recruitment Status : Completed
First Posted : March 21, 2006
Results First Posted : July 10, 2012
Last Update Posted : February 9, 2022
Juvenile Diabetes Research Foundation
National Institutes of Health (NIH)
Information provided by (Responsible Party):
University of Florida

Brief Summary:
While this study is now completely enrolled, we do hope to develop a "next generation" cord blood based study sometime in early 2009. Please continue to contact us if you have a child with newly diagnosed Type 1 Diabetes (T1D) who alo has their OWN cord blood in storage.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Procedure: Autologous Umbilical Cord Blood Transfusion Biological: Cord blood Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study
Study Start Date : April 2005
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Cord Blood
Umbilical Cord Blood
Procedure: Autologous Umbilical Cord Blood Transfusion
Cord Blood infusion
Other Name: Cord Blood

Biological: Cord blood
Develop Cord blood vaccine
Other Name: Vaccine

Primary Outcome Measures :
  1. Children With T1D Underwent a Single Autologous UCB Transfusion [ Time Frame: Baseline to Year 2 ]
    All participants were monitored for 2 years. Baseline and post-infusion mixed meal tolerance tests were performed to determine whether autologous cord blood infusion preserved endogenous insulin production. The change in median area under the curve for C-peptide (measure of insulin production) from baseline to to 2 years during a 2 hour mixed meal tolerance test was used as the primary outcome measure and was reported in ng/ml/120 minutes

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must have a diagnosis of T1D and have stored umbilical cord blood in an AABB and/or FACT accredited cord bank.
  2. TID diagnosis will be defined as having a clear history of polydipsia, polyphagia, polyuria, and weight loss consistent with a clinical diagnosis, diagnosis will mot be based solely upon the presence of autoantibodies.
  3. Cord blood meets all selection and testing criteria (see below).
  4. Able to complete mixed meal tolerance / glucagon stimulation test.
  5. Normal screening values for CBC, Renal function and electrolytes (BMP).
  6. Willing to comply with intensive diabetes management

Exclusion Criteria:

  1. Complicating medical issues that would interfere with blood drawing or monitoring.
  2. Chronic use of steroids or other immunosuppressive agents for other conditions.
  3. Positive infectious disease markers from mothers' blood or cord at time of collection (See below for details).
  4. Any evidence of illness on planned infusion date (i.e. fever >38.5 C, vomiting, diarrhea, wheezing, or crackles).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00305344

Layout table for location information
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
Sponsors and Collaborators
University of Florida
Juvenile Diabetes Research Foundation
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Michael J Haller, MD University of Florida
Principal Investigator: Desmond A Schatz, MD University of Florida
Publications of Results:
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT00305344    
Other Study ID Numbers: 1-2005-362
GCRC 593 ( Other Identifier: General Clinical Research Center )
UF IRB-01 125-2004 ( Other Identifier: UF Institutional Review Board )
First Posted: March 21, 2006    Key Record Dates
Results First Posted: July 10, 2012
Last Update Posted: February 9, 2022
Last Verified: February 2022
Keywords provided by University of Florida:
Type 1 Diabetes Mellitus
Umbilical Cord
Islets of Langerhans
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs